Compare ARK Genomic Revolution ETF (ARKG) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Quantumscape Corp — how do they compare? ARK Genomic Revolution ETF trades at $44.29, while Quantumscape Corp trades at $6.37 (market cap $3.81B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | QS | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $44.55 | $18.44 |
52-Week Low | $24.02 | $4.89 |
Market Cap | — | $3.81B |
Enterprise Value | — | $3.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
QuantumScape (QS) trades at $6.075, up 9.86% in the last session, with a bullish technical signal overall despite mixed moving averages and oscillators. The company reported a net loss of $435.05 million in 2025, with negative ROE and ROA, and has no revenue as it develops solid-state battery technology. Recent news highlights partnerships with Volkswagen and Honda, but the stock fell 31% in July 2026 amid commercialization delays.
The outlook remains speculative, with potential upside tied to successful battery commercialization by 2029, but high execution risks and persistent losses warrant caution. Analyst sentiment is neutral to bearish, with 73% hold ratings, reflecting uncertainty over timelines and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
